Is Medtronic (MDT) Becoming a Turnaround Story? Medtronic's recent quarterly results and UBS upgrade to Buy have sparked interest in the company's potential turnaround.
However, investors must separate fact from fiction in this narrative of resurgence. The numbers are undeniably impressive: Q4 revenue reached $9. 8 billion, up 9. 9% as reported and 6.
6% organic, with FY26 revenue totaling $36. 4 billion – an 8. 4% increase as reported and 5. 8% organic. However, these figures mask a more nuanced reality.